medroxyprogesterone acetate has been researched along with Neoplasms, Cystic, Mucinous, and Serous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bodurka, DC; Coleman, RL; Gershenson, DM; Lu, KH; Malpica, A; Sun, CC | 1 |
| Koskela-Niska, V; Lyytinen, H; Pukkala, E; Riska, A; Ylikorkala, O | 1 |
2 other study(ies) available for medroxyprogesterone acetate and Neoplasms, Cystic, Mucinous, and Serous
| Article | Year |
|---|---|
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Leuprolide; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Survival Rate; Tamoxifen; Triazoles; Watchful Waiting; Young Adult | 2017 |
Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.
Topics: Aged; Aged, 80 and over; Confidence Intervals; Estradiol; Estrogen Replacement Therapy; Female; Finland; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Norethindrone; Norethindrone Acetate; Ovarian Neoplasms; Postmenopause; Progestins; Risk Assessment; Time Factors | 2013 |